FOXO4-DRI Research Guide

Full name: FOXO4-D-Retro-Inverso Peptide (Senolytic)

A D-retro-inverso peptide that disrupts FOXO4-p53 interaction in senescent cells, triggering selective apoptosis of senescent cells while sparing healthy cells.

How FOXO4-DRI Works

Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism.

Dosing Protocol

• Typical dose: 5-10 mg/kg (animal studies)
• Frequency: 3x per week for 3 weeks
• Duration: 3-week cycles
• Route: Subcutaneous

Reported Benefits

• Selective senescent cell elimination
• Potential aging reversal
• Improved tissue function
• Reduced inflammatory burden
• Hair regrowth (mice)

Potential Side Effects

• Limited human safety data
• Transient inflammatory response possible
• Theoretical beneficial-senescence depletion

Research Citations

1. Targeted apoptosis of senescent cells restores tissue homeostasis (2017) - Selectively induced apoptosis in senescent cells, restored fitness, fur density, and renal function in aged mice.
2. FOXO4-p53 disruption as senolytic strategy (2021) - Cleared 60% of senescent cells in aged livers with reduced SASP inflammatory markers.

Related Anti-Aging Compounds

• Epithalon - Full Profile
• NAD+ - Full Profile
• Humanin - Full Profile
• SS-31 (Elamipretide) - Full Profile
• GDF-11 - Full Profile
• Glutathione - Full Profile

View full FOXO4-DRI profile with 3D molecule viewer →